-+ 0.00%
-+ 0.00%
-+ 0.00%
Reported Earlier, AstraZeneca’s Alexion Wins US Accelerated Approval For Ultomiris As First C5 Inhibitor To Reduce Proteinuria In IgA Nephropathy Adults; Phase III I CAN Shows 43.4% Reduction Versus Placebo At 34 Weeks
Share
Listen to the news
  • Based on I CAN Phase III trial results from prespecified interim analysis in which Ultomiris demonstrated 43.4% reduction in proteinuria vs placebo at 34 weeks 
  • Late-breaking results from I CAN Phase III trial will be presented at American Society of Nephrology’s Kidney Week 2026
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending